Skip to main content
SpringerLink
Log in

The role of biomarkers in the choice of therapy in breast cancer

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

The discovery of prognostic and predictive biomarkers, enabling the application of more individualized therapies to different molecular breast cancer (BC) subtypes, has already led to changes in BC treatment during the past decades. In this review, the importance of established as well as of emerging biomarkers, currently undergoing testing for technical validity and clinical utility, is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  2. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res. 2007;9:R28.

    Article  PubMed  Google Scholar 

  3. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–4.

    Article  CAS  PubMed  Google Scholar 

  4. Cuppone F, Bria E, Carlini P, et al. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer. 2008;113(2):238–46.

    Article  CAS  PubMed  Google Scholar 

  5. Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early stage breast cancer. Nat Rev Clin Oncol. 2009;7(1):22–36.

    Article  PubMed  Google Scholar 

  6. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26(12):1987–92.

    Article  CAS  PubMed  Google Scholar 

  7. Montemurro M, Aglietta M. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. Endocr Relat Cancer. 2009;16(4):1091–1102.

    Article  PubMed  Google Scholar 

  8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N Engl J Med. 2005;353:1659–72.

    Article  CAS  PubMed  Google Scholar 

  9. Viani GA, Afonso SL, Stefano AJ, et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.

    Article  PubMed  Google Scholar 

  10. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–918.

    Article  CAS  PubMed  Google Scholar 

  11. Seruga B, Ocana A, Niraula S, et al. Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more? J Clin Oncol. 2010;28:346–7.

    Article  Google Scholar 

  12. Hinestrosa MC, Dickersin K, Klein P, et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nature. 2007;7:309–15.

    CAS  Google Scholar 

  13. Mc Shane LM, Altmann DG, Sauerbrei W, et al. Reporting recommendations for tumour marker prognostic studies. J Clin Oncol. 2005;23:9067–72.

    Article  Google Scholar 

  14. Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Rel Cancer. 2010;17:245–62.

    Article  Google Scholar 

  15. Jensen EV, Desombre ER, Hurst DJ, et al. Estrogen receptor interactions in target tissues. Arch Anat Microsc Morphol Exp. 1967;56:547–69.

    CAS  PubMed  Google Scholar 

  16. Mc Guire WL. Estrogen receptors in human breast cancer. J Clin Invest. 1973;52:73–7.

    Article  CAS  Google Scholar 

  17. Fisher B, Redmond A, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981;305:1–6.

    Article  CAS  PubMed  Google Scholar 

  18. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11:597–608.

    Article  CAS  PubMed  Google Scholar 

  19. Yu KD, Shao ZM. ESR1 gene amplification: another mechanism regulating the cellular levels of ER-a. Nat Rev Cancer. 2011;11:823.

    Article  CAS  PubMed  Google Scholar 

  20. Hammond EMH, Haye DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.

    Article  PubMed  Google Scholar 

  21. Lydon JP, Edwards DP. Finally! A model for progesterone receptor action in normal human breast. Endocrinology. 2009;150(7):2988.

    Article  CAS  PubMed  Google Scholar 

  22. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25(25):3846–52.

    Article  PubMed  Google Scholar 

  23. Wolff AC, Hammond ME, Schwartz JN, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.

    Article  CAS  PubMed  Google Scholar 

  24. Perez EA, Dueck AC, McCullough AE, et al. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP Her2 positive criteria. J Natl Cancer Inst. 2012;104(2):159–62.

    Article  CAS  PubMed  Google Scholar 

  25. Bartlett JM, Munro AF, Dunn JA, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010;11(3):266–74.

    Article  CAS  PubMed  Google Scholar 

  26. Luprsi E, Andre F, Spyratos F, et al. KI 67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. BC Res Treat. 2011.

  27. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.

    Article  CAS  PubMed  Google Scholar 

  28. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829–34.

    Article  PubMed  Google Scholar 

  29. Macis D, Cazzaniga M, De Censi A, et al. Role of traditional and new biomarkers in breast cancer carcinogenesis. ecancer. 2009;3:157.

    CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that there is no actual or potential conflict of interest in relation to this article.

Author information

Authors and Affiliations

  1. 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory of Immunological and Molecular Cancer Research (LIMCR), Center for Clinical Cancer and Immunology Trials, Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT), Private Medical University Hospital Salzburg, Müllner Hauptstrasse 48, 5020, Salzburg, Austria

    Brigitte Mlineritsch MD, Sigrun Ressler MD &  Richard Greil MD

Authors
  1. Brigitte Mlineritsch MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sigrun Ressler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Greil MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brigitte Mlineritsch MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mlineritsch, B., Ressler, S. & Greil, R. The role of biomarkers in the choice of therapy in breast cancer. memo 5, 101–104 (2012). https://doi.org/10.1007/s12254-012-0027-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-012-0027-y

Keywords

Search

Navigation